We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00909051
First Posted: May 27, 2009
Last Update Posted: January 19, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bayer
May 26, 2009
May 27, 2009
January 19, 2012
March 2009
December 2010   (Final data collection date for primary outcome measure)
Data collection on patients weight and waist circumference, fasting blood glucose, postprandial blood glucose (2h), HbA1C; exploratory analysis according to patient groups (concomitant cardiovascular disease groups, BMI) [ Time Frame: During observation period of three months ]
Same as current
Complete list of historical versions of study NCT00909051 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups
Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups
Evaluation of safety and effectiveness of Glucobay® under daily-life treatment conditions in a large sample of patients.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
  • Patients with untreated or pretreated diabetes mellitus type 2
  • No Glucobay® intake within the last 3 months before documentation of initial visit
  • Exclusion Criteria: contraindication stated in the local Glucobay® product information; warnings and precautions must be considered.
Diabetes Mellitus
Drug: Acarbose (Glucobay, BAYG5421)
Patients with diabetes type 2 newly treated with Glucobay
Group 1
Intervention: Drug: Acarbose (Glucobay, BAYG5421)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15729
December 2010
December 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with untreated or pretreated diabetes mellitus or patients for which acarbose is indicated and without acarbose treatment within the last three months before study inclusion. The decision for treatment type and duration is taken by the investigator and is made before inclusion into the study.

Exclusion Criteria:

  • Exclusion criteria must be read in conjunction with the local product information.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Algeria,   Bosnia and Herzegovina,   Cambodia,   China,   Hong Kong,   India,   Indonesia,   Korea, Republic of,   Malaysia,   Moldova, Republic of,   Pakistan,   Philippines,   Russian Federation,   Singapore,   Thailand,   Vietnam
Croatia
 
NCT00909051
14284
GB0701 ( Other Identifier: Company internal )
No
Not Provided
Not Provided
Medical Affairs Therapeutic Area Head, Bayer HealthCare AG
Bayer
Not Provided
Study Director: Bayer Study Director Bayer
Bayer
January 2012